Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 66

  • Unknown sort schema '{last_sort_schema}' ignored
  • The following term was not found in PubMed: R%5BAuthor%5D.
1.

Malignant Peritoneal Mesothelioma Presenting as Mucinous Ascites.

Field Z, Zori A, Khullar V, Mota M, Feely M, Firpi RJ.

ACG Case Rep J. 2018 Mar 14;5:e23. doi: 10.14309/crj.2018.23. eCollection 2018.

2.

Liver Transplantation in the Twenty-First Century.

Firpi RJ.

Clin Liver Dis. 2017 May;21(2):xv-xvi. doi: 10.1016/j.cld.2017.02.001. No abstract available.

PMID:
28364825
3.

Biliary duct hamartomas in polycystic liver disease.

Schlachterman A, Hussain J, Firpi R.

BMJ Case Rep. 2015 Aug 13;2015. pii: bcr2015211141. doi: 10.1136/bcr-2015-211141. No abstract available.

4.

Hepatitis C: Treatment of difficult to treat patients.

Hilgenfeldt EG, Schlachterman A, Firpi RJ.

World J Hepatol. 2015 Jul 28;7(15):1953-63. doi: 10.4254/wjh.v7.i15.1953. Review.

5.

Hepatitis C cirrhosis: New perspectives for diagnosis and treatment.

Khullar V, Firpi RJ.

World J Hepatol. 2015 Jul 18;7(14):1843-55. doi: 10.4254/wjh.v7.i14.1843. Review.

6.

Sustained virological response to antiviral therapy in a randomized trial of cyclosporine versus tacrolimus in liver transplant patients with recurrent hepatitis C infection.

Duvoux C, Villamil F, Renner EL, Grazi GL, Firpi RJ, Pageaux G, Mulhaupt B, Schirm F, Rauer B, Bernhardt P, Levy G.

Ann Transplant. 2015 Jan 15;20:25-35. doi: 10.12659/AOT.892032.

7.

Hepatitis C management in post-transplant patients.

Hilgenfeldt E, Firpi RJ.

Minerva Gastroenterol Dietol. 2015 Mar;61(1):21-9. Epub 2014 Nov 12. Review.

PMID:
25390286
8.

Pre-and-post transplant considerations in patients with nonalcoholic fatty liver disease.

Khullar V, Dolganiuc A, Firpi RJ.

World J Transplant. 2014 Jun 24;4(2):81-92. doi: 10.5500/wjt.v4.i2.81. Review.

9.

Challenges of recurrent hepatitis C in the liver transplant patient.

Dhanasekaran R, Firpi RJ.

World J Gastroenterol. 2014 Apr 7;20(13):3391-400. doi: 10.3748/wjg.v20.i13.3391. Review.

10.

Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma.

Dhanasekaran R, Hemming AW, Zendejas I, George T, Nelson DR, Soldevila-Pico C, Firpi RJ, Morelli G, Clark V, Cabrera R.

Oncol Rep. 2013 Apr;29(4):1259-67. doi: 10.3892/or.2013.2290. Epub 2013 Feb 18.

11.

Recurrent hepatitis C virus infection post liver transplantation: impact of choice of calcineurin inhibitor.

Duvoux C, Firpi R, Grazi GL, Levy G, Renner E, Villamil F.

Transpl Int. 2013 Apr;26(4):358-72. doi: 10.1111/tri.12065. Epub 2013 Feb 18. Review.

12.

Hepatic preservation injury: severity of hepatitis C recurrence and survival after liver transplantation.

Michaels AJ, Dhanasekaran R, Foley DP, Alkhasawneh A, Dixon L, Soldevila-Pico C, Morelli G, Cabrera R, Clark VC, Firpi RJ.

Dig Dis Sci. 2013 May;58(5):1403-9. doi: 10.1007/s10620-012-2521-9. Epub 2013 Jan 10.

13.

Neutrophil-lymphocyte ratio predicts overall and recurrence-free survival after liver transplantation for hepatocellular carcinoma.

Limaye AR, Clark V, Soldevila-Pico C, Morelli G, Suman A, Firpi R, Nelson DR, Cabrera R.

Hepatol Res. 2013 Jul;43(7):757-64. doi: 10.1111/hepr.12019. Epub 2012 Nov 30.

14.

CC genotype donors for the interleukin-28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant.

Firpi RJ, Dong H, Clark VC, Soldevila-Pico C, Morelli G, Cabrera R, Norkina O, Shuster JJ, Nelson DR, Liu C.

Liver Int. 2013 Jan;33(1):72-8. doi: 10.1111/liv.12013. Epub 2012 Oct 29.

15.

The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma.

Cabrera R, Limaye AR, Horne P, Mills R, Soldevila-Pico C, Clark V, Morelli G, Firpi R, Nelson DR.

Aliment Pharmacol Ther. 2013 Jan;37(1):91-7. doi: 10.1111/apt.12098. Epub 2012 Oct 24.

16.

Particle swarm optimization-based feature selection for cognitive state detection.

Firpi HA, Vogelstein RJ.

Conf Proc IEEE Eng Med Biol Soc. 2011;2011:6556-9. doi: 10.1109/IEMBS.2011.6091617.

PMID:
22255841
17.

Management of recurrent hepatitis C infection after liver transplantation.

Limaye AR, Firpi RJ.

Clin Liver Dis. 2011 Nov;15(4):845-58. doi: 10.1016/j.cld.2011.08.003. Review.

PMID:
22032532
18.

Enhancers in embryonic stem cells are enriched for transposable elements and genetic variations associated with cancers.

Teng L, Firpi HA, Tan K.

Nucleic Acids Res. 2011 Sep 1;39(17):7371-9. doi: 10.1093/nar/gkr476. Epub 2011 Jun 17.

19.

The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma.

Cabrera R, Pannu DS, Caridi J, Firpi RJ, Soldevila-Pico C, Morelli G, Clark V, Suman A, George TJ Jr, Nelson DR.

Aliment Pharmacol Ther. 2011 Jul;34(2):205-13. doi: 10.1111/j.1365-2036.2011.04697.x. Epub 2011 May 23.

20.

Impact of transarterial therapy in hepatitis C-related hepatocellular carcinoma on long-term outcomes after liver transplantation.

Cabrera R, Dhanasekaran R, Caridi J, Clark V, Morelli G, Soldevila-Pico C, Magglioca J, Nelson D, Firpi RJ.

Am J Clin Oncol. 2012 Aug;35(4):345-50. doi: 10.1097/COC.0b013e31821631f6.

Supplemental Content

Loading ...
Support Center